{"id":26453,"date":"2023-04-10T15:17:16","date_gmt":"2023-04-10T18:17:16","guid":{"rendered":"https:\/\/mindthegraph.com\/blog\/the-last-of-us-science-copy\/"},"modified":"2023-04-25T08:31:20","modified_gmt":"2023-04-25T11:31:20","slug":"new-treatment-for-alzheimers","status":"publish","type":"post","link":"https:\/\/mindthegraph.com\/blog\/lv\/jauna-arstesana-dzimtenes-alzheimersa-limfodiagnostikas-arstesanai\/","title":{"rendered":"Kas ir jaunais Alcheimera slim\u012bbas \u0101rst\u0113\u0161anas l\u012bdzeklis - lekanemabs?"},"content":{"rendered":"

Alcheimera slim\u012bba un citas demences. saslimst\u012bba un izplat\u012bba pieauga par 147,95% un 160,84%.<\/a>attiec\u012bgi no 1990. l\u012bdz 2019. gadam. Tas nor\u0101da, cik izplat\u012bta ir k\u013cuvusi Alcheimera slim\u012bba, ko v\u0113l vair\u0101k sare\u017e\u0123\u012b fakts, ka nav \u0101rst\u0113\u0161anas l\u012bdzek\u013cu. <\/p>\n\n\n\n

Pacienti un apr\u016bp\u0113t\u0101ji jau ilgu laiku ir mekl\u0113ju\u0161i terapijas veidus, un katrs jauns p\u0113t\u012bjums vi\u0146iem sniedz jaunu cer\u012bbu.<\/p>\n\n\n\n

Jap\u0101nas farm\u0101cijas uz\u0146\u0113mums Eisai atkl\u0101ja vienu konkr\u0113tu medikamentu - jaunu Alcheimera slim\u012bbas \u0101rst\u0113\u0161anas l\u012bdzekli, kas uzlabo kognit\u012bv\u0101s funkcijas Alcheimera slim\u012bbas pacientiem, k\u0101 public\u0113ts izdevum\u0101 New England Journal of Medicine.<\/a><\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"
Ilustr\u0101cijas pieejamas Mind the Graph<\/a><\/strong><\/em><\/figcaption><\/figure>\n\n\n\n
<\/div>\n\n\n\n

<\/a>\u0160aj\u0101 rakst\u0101 par \u0161o inovat\u012bvo \u0101rst\u0113\u0161anu un to, k\u0101 t\u0101 var uzlabot Alcheimera slim\u012bbas pacientu dz\u012bves gaitu, atrad\u012bsiet skaidrojumu.<\/p>\n\n\n\n

Viss, kas jums j\u0101zina par jauno Alcheimera slim\u012bbas \u0101rst\u0113\u0161anu<\/h2>\n\n\n\n

\u0160\u012b jaun\u0101 Alcheimera slim\u012bbas \u0101rst\u0113\u0161anas metode ir medikaments ar nosaukumu Lecanemab, kas tika atkl\u0101ts 18 m\u0113ne\u0161u ilg\u0101 3. f\u0101zes p\u0113t\u012bjum\u0101, kur\u0101 piedal\u012bj\u0101s cilv\u0113ki vecum\u0101 no 50 l\u012bdz 90 gadiem ar agr\u012bnu Alcheimera slim\u012bbu. Lai var\u0113tu piedal\u012bties eksperiment\u0101, \u0161iem cilv\u0113kiem j\u0101b\u016bt vid\u0113ji smagiem kognit\u012bviem trauc\u0113jumiem vai vieglas pak\u0101pes demencei, ko izrais\u012bjusi Alcheimera slim\u012bba, k\u0101 ar\u012b smadzen\u0113s j\u0101b\u016bt amilo\u012bda pl\u0101ksn\u012b\u0161u paz\u012bm\u0113m.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"
Ilustr\u0101cijas pieejamas Mind the Graph<\/a><\/strong><\/em><\/figcaption><\/figure>\n\n\n\n
<\/div>\n\n\n\n

<\/a>Pacienti \u0161aj\u0101 eksperiment\u0101 sa\u0146emtu vai nu intravenozi lekanemabu, vai placebo. Izmai\u0146as tika m\u0113r\u012btas p\u0113c 18 m\u0113ne\u0161iem. P\u0113c \u0161\u012b perioda pacientiem ar Alcheimera agr\u012bn\u0101s stadijas slim\u012bbu, kuri lietoja Lecanemabu, bija v\u0113rojama 27% maz\u0101k kognit\u012bvo trauc\u0113jumu<\/strong> nek\u0101 tie, kuri sa\u0146\u0113ma placebo. Tas atbilst 0,45 punktiem 18 punktu CDR-SB skal\u0101.<\/p>\n\n\n\n

Alcheimera slim\u012bbas p\u0113tnieku galvenais m\u0113r\u0137is bija atrast veiksm\u012bgu \u0101rst\u0113\u0161anas l\u012bdzekli, lai c\u012bn\u012btos ar slim\u012bbas galveno punktu - smadze\u0146u amilo\u012bda pl\u0101ksn\u012bt\u0113m, kas ir olbaltumviela, kura boj\u0101 neironus un citas \u0161\u016bnas. \u0160is prote\u012bns rodas, sadaloties liel\u0101kam prote\u012bnam, ko sauc par amilo\u012bda prekursora prote\u012bnu.<\/p>\n\n\n\n

L\u012bdz \u0161im jauna Alcheimera slim\u012bbas \u0101rst\u0113\u0161anas l\u012bdzek\u013ca un medikamenta, kas sp\u0113tu blo\u0137\u0113t amilo\u012bda pl\u0101ksn\u012btes un vienlaikus mazin\u0101t simptomus, atra\u0161ana ir gandr\u012bz zaud\u0113ts kar\u0161. Tom\u0113r lekanemabs bija pirmais medikaments, kam tas izdev\u0101s. <\/p>\n\n\n\n

Pag\u0101tn\u0113 ir veikti daudzi citi p\u0113t\u012bjumi, kas l\u012bdzin\u0101s \u0161im, un l\u012bdz\u012bgu rezult\u0101tu nav g\u016bti. Piem\u0113ram, Aducanumab, paz\u012bstams ar\u012b k\u0101 Aduhelm, ir z\u0101les, kas k\u013cuva pieejamas 2021. gad\u0101. L\u012bdz\u012bgi k\u0101 Lecanemab\u0101, ar\u012b Aducanumaba sa\u0146\u0113m\u0113jiem uzlaboj\u0101s kognit\u012bvie testi, sal\u012bdzinot ar tiem, kuri lietoja placebo. Aducanumaba iedarb\u012bba tika atkl\u0101ta agr\u0101k veikt\u0101 1. f\u0101zes p\u0113t\u012bjum\u0101, kur\u0101 piedal\u012bj\u0101s maz\u0101ks pacientu skaits un kura m\u0113r\u0137is bija p\u0101rbaud\u012bt terapijas dro\u0161\u012bbu, nevis t\u0101s efektivit\u0101ti. <\/p>\n\n\n\n

T\u0101 k\u0101 3. f\u0101zes p\u0113t\u012bjumos z\u0101\u013cu priek\u0161roc\u012bbas netika ticami un konsekventi atk\u0101rtotas, Medic\u012bnas un medic\u012bnas pakalpojumu centrs nol\u0113ma neapmaks\u0101t z\u0101\u013cu augst\u0101s izmaksas, kas maks\u0101 $56,000 gad\u0101 un prasa vair\u0101k p\u0113t\u012bjumu, lai noteiktu \u0101rst\u0113\u0161anas efektivit\u0101ti. <\/p>\n\n\n\n

Lai gan abas z\u0101les \u0161\u0137iet sal\u012bdzino\u0161i l\u012bdz\u012bgas, ir b\u016btiski uzsv\u0113rt, cik at\u0161\u0137ir\u012bgi t\u0101s iedarbojas, t\u0101p\u0113c zin\u0101tnieki uzskata, ka Lecanemabam b\u016bs daudz liel\u0101ka ietekme Alcheimera slim\u012bbas gaitas p\u0101rveido\u0161an\u0101. Adukanumabs mijiedarbojas ar amilo\u012bda olbaltumviel\u0101m, kas jau ir sagrup\u0113tas. Savuk\u0101rt lekanemabs iedarbojas \u0101tr\u0101k, m\u0113r\u0137\u0113jot uz \"protofibril\u0101m\" jeb filamentiem, kas galu gal\u0101 p\u0101rtaps pl\u0101ksn\u012bt\u0113s.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\"\"
Ilustr\u0101cijas pieejamas Mind the Graph<\/a><\/strong><\/em><\/figcaption><\/figure>\n\n\n\n
<\/div>\n\n\n\n

<\/a>Vai ir k\u0101das blakuspar\u0101d\u012bbas?<\/h2>\n\n\n\n

\u0160\u0137iet, ka l\u012bdz \u0161im lekanemabam ir maz\u0101k blakuspar\u0101d\u012bbu nek\u0101 adukanumabam. Uz\u0146\u0113mums Eisai, kas veica p\u0113t\u012bjumu, apgalvoja, ka 12,6% pacientu cieta no ARIA-E smadze\u0146u iekaisuma, kas var b\u016bt n\u0101v\u0113jo\u0161s, bet ir \u0101rst\u0113jams, ja z\u0101\u013cu lieto\u0161ana tiek p\u0101rtraukta vai samazin\u0101ta deva. <\/p>\n\n\n\n

No otras puses, aptuveni vienai tre\u0161da\u013cai adukanumabu sa\u0146\u0113mu\u0161o pacientu ARIA-E att\u012bst\u012bj\u0101s ARIA-E \u0101rst\u0113\u0161anas laik\u0101. z\u0101\u013cu 3. f\u0101zes p\u0113t\u012bjum\u0101. <\/a><\/p>\n\n\n\n

Lecanemaba eksperimenta laik\u0101 nomira 13 pacienti, un tie bija gandr\u012bz vienm\u0113r\u012bgi sadal\u012bti pa \u0101rst\u0113\u0161anas un placebo grup\u0101m - septi\u0146i n\u0101ves gad\u012bjumi bija \u0101rst\u0113\u0161anas grup\u0101 un se\u0161i - placebo grup\u0101. <\/p>\n\n\n\n

Pirms z\u0101\u013cu izlai\u0161anas FDA izskat\u012bs visu, kas notika eksperimenta laik\u0101, tostarp 13 n\u0101ves gad\u012bjumus. Tom\u0113r pagaid\u0101m z\u0101les \u0161\u0137iet daudzsolo\u0161as.<\/p>\n\n\n\n

P\u0101rv\u0113rsiet savus datus viegli saprotam\u0101 veid\u0101<\/h2>\n\n\n\n

Saska\u0146\u0101 ar p\u0113t\u012bjums,<\/a> cilv\u0113ka smadzenes ir rad\u012btas, lai apstr\u0101d\u0101tu vizu\u0101lus att\u0113lus, un t\u0101s to var dar\u012bt milz\u012bg\u0101 \u0101trum\u0101. Att\u0113lus var uztvert vismaz divreiz \u0101tr\u0101k nek\u0101 tekstu. T\u0101p\u0113c izmantojiet \u0161o inform\u0101ciju sav\u0101 lab\u0101 un izv\u0113lieties t\u0101du r\u012bku k\u0101 Mind The Graph, lai viegli izveidotu est\u0113tiski pievilc\u012bgus materi\u0101lus savam darbam, kas var p\u0101rv\u0113rst lielu teksta apjomu iespaid\u012bgos un viegli p\u0101rskat\u0101mos vizu\u0101los materi\u0101los.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n